Merck (MRK) Receivables (2009 - 2026)

Merck has disclosed Receivables across 18 years of filings, most recently posting $12.2 billion for Q1 2026.

• In Q1 2026, Receivables rose 13.16% year-over-year to $12.2 billion; the TTM figure through Mar 2026 stood at $12.2 billion (up 13.16% YoY), while the FY2025 annual figure was $11.8 billion, up 14.57% from the prior year.
• Receivables grew to $12.2 billion in Q1 2026, from $11.8 billion in the prior quarter.
• Over the last five years, Receivables for MRK reached as high as $12.2 billion in Q1 2026 and fell as low as $717.0 million in Q1 2023.
• The 5-year median for Receivables is $10.8 billion (2025), against an average of $9.8 billion.
• Annual changes were most pronounced in 2022 — Receivables soared 15410.29% — and 2023, when it tumbled 93.2%.
• A 5-year view of Receivables shows it stood at $10.0 billion in 2022, then gained by 3.9% to $10.3 billion in 2023, then declined by 0.69% to $10.3 billion in 2024, then gained by 14.57% to $11.8 billion in 2025, then climbed by 3.69% to $12.2 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $12.2 billion, $11.8 billion, and $12.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.